A Multicenter, Open-label, Dose-escalation Phase I/II Clinical Study to Evaluate the Safety, Preliminary Efficacy and Immunogenicity of SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Genetic
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This is a phase I/II clinical study to evaluate the safety, preliminary efficacy and immunogenicity of SKG0201 injection in subjects with Spinal Muscular Atrophy Type I.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 6 months
Healthy Volunteers: f
View:
• Type I SMA, defined by bi-allelic mutations in the SMN1 gene.
• Clinical history and signs are consistent with type I SMA, such as hypotonia, delayed motor function development, and poor head control.
• On the day of administration, the age of the subjects do not exceed 180 days after birth.
Locations
Other Locations
China
Peking University First Hospital
RECRUITING
Beijing
Children's Hospital, Zhejiang University School of Medicine
RECRUITING
Hangzhou
Children's Hospital of Fudan University
RECRUITING
Shanghai
Contact Information
Primary
Yongqin Wang
yongqin.wang@skytx.com
+86 18616737445
Time Frame
Start Date: 2026-07-15
Estimated Completion Date: 2029-05-25
Participants
Target number of participants: 11
Treatments
Experimental: Dose-escalation
Dosage form: Injection Frequency of administration: one-time deliver
Related Therapeutic Areas
Sponsors
Leads: Lanyue Biotech (Hangzhou) Co., Ltd.